Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.dib.2020.106445 http://scihub22266oqcxt.onion/10.1016/j.dib.2020.106445 33110933!7582040!33110933     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33110933&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Data+Brief 2020 ; 33 (?): 106445 Nephropedia Template TP {{tp|p=33110933|t=2020. Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients |pdf=|usr=}}{{33110933}} gab.com Text Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients JO: Data Brief http://www.kidney.de/pget.php?&tw=1&pmid=33110933 #FOAvip The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including different Ebola and HIV antivirals, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Authorized medicaments manipulation is sometimes necessary because they are not always formulated to be administered to non-cooperative patients or they are in shortage. It is this the case of the fixed combination of lopinavir/ritonavir, which was extensively used in the first phase of the outbreak inducing a shortage of the oral solution available in the EU market. This work provides data on size distribution, osmolarity other than drug chemical stability of a lopinavir/ritonavir extemporaneous preparation made by using the solid dosage form (i.e., tablet) available on the market as drug source. The reported data indicate that such preparation is suitable to be delivered through a nasogastric tube, and enough stable for two weeks from the preparation at room temperature. Twit Text FOAVip Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients ????Data Brief http://www.kidney.de/pget.php?&tw=1&pmid=33110933 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33110933 #FOAvip English Wikipedia <ref>{{Cite pmid|33110933}}</ref> Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients #MMPMID33110933 Zanon D; Musazzi UM; Manca A; De Nicolo A; D'Avolio A; Cilurzo F; Maximova N; Tomasello C; Clementi E; Minghetti P Data Brief 2020[Dec]; 33 (?): 106445 PMID33110933show ga The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including different Ebola and HIV antivirals, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Authorized medicaments manipulation is sometimes necessary because they are not always formulated to be administered to non-cooperative patients or they are in shortage. It is this the case of the fixed combination of lopinavir/ritonavir, which was extensively used in the first phase of the outbreak inducing a shortage of the oral solution available in the EU market. This work provides data on size distribution, osmolarity other than drug chemical stability of a lopinavir/ritonavir extemporaneous preparation made by using the solid dosage form (i.e., tablet) available on the market as drug source. The reported data indicate that such preparation is suitable to be delivered through a nasogastric tube, and enough stable for two weeks from the preparation at room temperature. ?Data on compounding lopinavir and ritonavir suspension for non-coopera(epmc).pdf DeepDyve Pubget Overpricing